A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SRK-181 ADMINISTERED ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (DRAGON)

About

Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
PRE22-006859
Category
Hematology-Oncology
Oncology
Contact
Kimberly Kelly
Location
  • TRIO-US - Ft. Wayne IN
  • TRIO-US - Fullerton